Table 2.
Treatment characteristics
| Variable | N (%) |
|---|---|
| Boost approach | |
| SeqB | 103 (54.3) |
| SIB | 87 (45.7) |
| SIB dose and fractionation | |
| PTV dose-tumor (Gy) | |
| 54 Gy/30 fractions | 57 (65.5) |
| 50.4 Gy/28 fractions | 30 (34.5) |
| PTV dose-positive nodes (Gy) (26 pts) | |
| 50.4 Gy/30 fractions | 26 (100.0) |
| PTV dose-negative nodes (Gy) | |
| 45 Gy/30 fractions | 53 (60.9) |
| 42 Gy/28 fractions | 34 (39.1) |
| SeqB dose and fractionation | |
| PTV dose-first sequence | |
| 36 Gy/20 fractions | 103 (100) |
| PTV dose-sequential boost | |
| 23,4 Gy/13 fractions | 103 (100) |
| Chemotherapy regimens | |
| 5-FU + MMC × 2 cycles | 159 (83.7) |
| 5-FU + MMC × 1 cycle | 2 (1.0) |
| Capecitabine + MMC × 2 cycles | 26 (13.7) |
| Capecitabine + MMC × 1 cycle | 3 (1.6) |
Legend, SeqB sequential boost, SIB simultaneous integrated boost, PTV planning target volume, Gy Gray, pts patients, 5-FU 5-fluorouracil, MMC mitomycin C